Poland· PL-100386137

Olumiant

A baricitinib product containing baricitinibum, registered in Poland by Eli Lilly Nederland B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L04AF02

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about baricitinibumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Baricitinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AF02 (baricitinib), each read from that country’s own register.

This record: Poland, from URPL (Poland)
7 of them publish a price we can compare per daily dose

Search baricitinib products by name

Baricitinib · ATC L04AF02

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of baricitinib costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $26.41 in France to $138.66 in United States — a ×5.2 gap.

3 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Baricitinib · price per daily dose (3 mg)

USD · FX 28 Sept 2026

US United States$138.66 (acquisition cost)
CH Switzerland$62.27
FR France$26.41

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Baricitinibum
Manufacturer: Eli Lilly Nederland B.V.
Country: Poland (PL)
ATC code: L04AF02
ATC class: Baricitinib
Defined daily dose: 3 mg, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 2

gtin
05014602401269
gtin
03837000170825

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

368 interactions on record for baricitinib.

Graded by severity as the source publishes them — 295 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check baricitinib against other medicines How interaction checks work

Baricitinib · interactions on record

368 records

295 severe
67 moderate
6 minor

Most severe, free to view

PrednisoloneA07EA01severe
HydrocortisoneA07EA02severe
PrednisoneA07EA03severe
BetamethasoneA07EA04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Baricitinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All baricitinib products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

Iceland · Olumiant
Liechtenstein · Olumiant
Norway · Olumiant
Portugal · Baricitinib Generis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/da5dbd17-efc9-4a16-bbf7-e8f0e625f351
GET /v1/drugs/da5dbd17-efc9-4a16-bbf7-e8f0e625f351?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "4 mg",
  "packaging": "Rpz ¦ EU/1/16/1170/009 ¦ 121505\n14 tabl.\n05014602401269 ¦ Rpz ¦ EU/1/16/1170/010 ¦ 121506\n28 tabl. w blistrze\n¦ UR/Z/4c/013/22 - 05014602401269 ¦ UR/Z/4c/007/22 - 05014602401269 ¦ UR/Z/4c/017/21 - 05014602401269 ¦ UR/Z/4c/010/21 - 05014602401269 ¦ UR/Z/4c/011/21 - 05014602401269 ¦ UR/Z/4c/030/22 - 05014602401269 ¦ UR/Z/4c/032/22\nRpz ¦ EU/1/16/1170/011 ¦ 121507\n28 tabl. w blistrze perforowanym\n03837000170825 ¦ Rpz ¦ EU/1/16/1170/012 ¦ 121508\n35 tabl.\nRpz ¦ EU/1/16/1170/013 ¦ 121509\n56 tabl.\nRpz ¦ EU/1/16/1170/014 ¦ 121510\n84 tabl. w blistrze\nRpz ¦ EU/1/16/1170/015 ¦ 121511\n84 tabl. w blistrze perforowanym\nRpz ¦ EU/1/16/1170/016 ¦ 121512\n98 tabl.",
  "substance": "Baricitinibum 4 mg",
  "common_name": "Baricitinibum",
  "pl_product_id": "100386137",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

API reference MCP server Plans

See everything about baricitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console